ReviewBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2014

Management of relapsed or refractory hodgkin lymphoma with second-generation antibody-drug conjugates: focus on brentuximab vedotin.

Matthew Mei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.